Navigation Links
DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call
Date:7/27/2009

CUPERTINO, Calif., July 27 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 3, 2009 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
2. DURECT Corporation Invites You to Join its First Quarter 2009 Earnings Conference Call
3. DURECT to Participate in Cowen and Company Healthcare Conference
4. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
5. DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference Call
6. DURECT Corporation to Participate in Upcoming Healthcare Conferences
7. DURECT Corporation to Participate in Upcoming Healthcare Conferences
8. DURECT Corporation Invites You to Join Its Third Quarter 2008 Earnings Conference Call
9. DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology
10. DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call
11. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... California (PRWEB) , ... September 25, 2017 , ... ... to announce the launch of its new website. No need to be ... has the answer. Go to welldonedesigns.com where all orders are printed and shipped ...
(Date:9/25/2017)... ... September 25, 2017 , ... Catalent ... for drugs, biologics and consumer health products, today announced that two of its ... of bioassays at two upcoming conferences. , At the BEBPA 10th Annual Bioassay ...
(Date:9/25/2017)... ... ... NCPDP Foundation , a 501(c)(3) nonprofit charitable organization ... grant to Johns Hopkins Medicine to address patient safety risk by implementing CancelRx ... a prescription already submitted to a pharmacy. Studies indicate that up to 3% ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... and efficiency. The principle of First-Defect-Stop for laboratory weighing is designed ... have the chance to have negative consequences on downstream processes. , If a ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... science and technology-enabled services supporting clinical research, today announces that 30 of ... aspects of the drug development lifecycle at upcoming industry conferences and webinars. ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), ... partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry technology ... leading mobile spirometry platform and Novartis, commitment to address the ... ... ...
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... WILMINGTON, Del. , Sept. 6, 2017 NeuroRx, ... for Acute Suicidal Ideation and Behavior (ASIB), has been granted ... for its sequential therapy of NRX-100 (ketamine HCl) followed by ... patients in a pivotal trial of this sequential therapy targeting ... bipolar depression. 1 ...
Breaking Medicine Technology: